EXPAREL: Revolutionizing Post-Surgical Pain Relief

Pacira BioSciences' EXPAREL: A Leap Forward in Opioid-Sparing Pain Management

In a decisive advancement for post-surgical pain management, Pacira BioSciences, Inc. (NASDAQ:PCRX) has unveiled promising Phase 3 study outcomes for EXPAREL (bupivacaine liposome injectable suspension), underlining its effectiveness in significantly reducing pain and opioid use post-operation. Published in the reputable Journal of Clinical Anesthesia, these findings mark a pivotal step forward in the clinical approach toward managing pain without the reliance on opioids, thereby addressing a critical issue in outpatient procedures.